reviewed consolidated financial statement ended March 31, 2018, the total transaction size of the investment in this new subsidiary based on the total value of consideration paid criteria, is equivalent to
completed in Q2/2018, namely, Lumpini Ville Phra Nang Klao-Riverview and one real estate project for investment, namely, Lumpini Township Rangsit-Klong 1 (Phase 3), Building F1. Three new projects are
million due to the slowdown of investment environment throughout the country. Cost of goods sold and services decreased in portion of decreasing revenue but expenses were At the same level as last year. The
performance of the company. Since in the quarter 2/2018, these units has operating loss. The subsidiary will use the proceeds as working capital for investment in the trading business of Non-Destructive Testing
166.69 Million Baht compare with at the end of last year by net cash flow provided by operation activities were 198.22 Million Baht, cash flow from investment activities were 19.53 Million Baht and net
Financial Position Analysis Unit : MB As at 30 September 2018 As at 31 December 2017 Change MB % Cash and cash equivalents 92.16 124.63 -32.47 -26.06% Current investment 155.85 252.71 -96.86 -38.33
quarter 3 /2017 as the principal of investment declined bringing down the yield. Jan – Sep. 2018 For the first 9-month of 2018, sales increased to THB 620.53 million or 18% from THB 525.24 million in 9
standard in 3rd quarter 2017. 4. The effect from impairment of investment in subsidiaries Bath 4.04 million. This transaction was loss recognize in 3rd quarter 2018 when the liquidation completed. Please be
million baht to 10.9 million baht. Meanwhile, income from property rental dropped 17% from 97.7 million baht to 81.3 million baht due to the decrease in warehouse rental. Dividend from investment dropped
the liquidation of Solvay Biochemicals (Taixing) Limited were fully booked in 2017. 4. 93 MB loss on dilution on investment in an associate was recorded from the change in the Company’s ownership